AUFBAU HOLDINGS LIMITED

AUFBAU Holdings Limited is a cutting‑edge biotechnology company dedicated to developing novel diagnostics and therapeutics for the treatment of cancer and eye diseases. By harnessing advanced molecular‑biology platforms, AUFBAU creates innovative tools that enable earlier, more accurate disease detection and the delivery of targeted therapies designed to improve patient outcomes.

The company’s portfolio centres on two high‑impact areas: oncology and ophthalmology. In oncology, AUFBAU focuses on biomarkers and therapeutic agents that can pinpoint malignant cells and intervene with precision. In the field of eye health, it pursues diagnostic assays and treatment modalities aimed at tackling conditions that threaten vision. AUFBAU’s work serves clinicians, researchers and, ultimately, the patients who rely on breakthrough medical solutions.

With a clear mission to translate scientific discovery into real‑world health benefits, AUFBAU Holdings Limited positions itself as a trusted partner for the global healthcare community.